tildrakizumab
Sign in to saveTildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.
~7 min read
Encyclopedic overview
8 sectionsContents
- Medical use
- History
- Mechanism of action
- Administration
- Clinical trials
- Side effects
- Approvals and indications
- References
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.
Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.
Excerpted from Wikipedia’s “tildrakizumab” article, available under the CC BY-SA 4.0 licence.